KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Net Income towards Common Stockholders (2018 - 2025)

Historic Net Income towards Common Stockholders for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to -$501000.0.

  • Castle Biosciences' Net Income towards Common Stockholders fell 12208.02% to -$501000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.2 million, marking a year-over-year decrease of 30085.6%. This contributed to the annual value of $18.2 million for FY2024, which is 13174.92% up from last year.
  • Castle Biosciences' Net Income towards Common Stockholders amounted to -$501000.0 in Q3 2025, which was down 12208.02% from $4.6 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Net Income towards Common Stockholders ranged from a high of $9.6 million in Q4 2024 and a low of -$29.2 million during Q1 2023
  • Its 5-year average for Net Income towards Common Stockholders is -$8.4 million, with a median of -$6.4 million in 2021.
  • As far as peak fluctuations go, Castle Biosciences' Net Income towards Common Stockholders tumbled by 103938.11% in 2023, and later skyrocketed by 47170.54% in 2024.
  • Over the past 5 years, Castle Biosciences' Net Income towards Common Stockholders (Quarter) stood at -$6.4 million in 2021, then tumbled by 220.65% to -$20.6 million in 2022, then skyrocketed by 87.49% to -$2.6 million in 2023, then soared by 471.71% to $9.6 million in 2024, then crashed by 105.22% to -$501000.0 in 2025.
  • Its Net Income towards Common Stockholders stands at -$501000.0 for Q3 2025, versus $4.6 million for Q2 2025 and -$25.8 million for Q1 2025.